Key Accomplishments of 2025

FibroBiologics marked significant milestones in its journey toward advancing fibroblast-derived therapies in 2025. The company's expansion included:

• Opening a new, state-of-the-art laboratory in Houston, spanning over 10,000 square feet, designed to enhance research and development capabilities.
• Closing multiple registered direct offerings, raising vital capital totaling $4 million from an existing shareholder in November, along with $1.5 million later that month and $1.7 million in December.
• Eliminating all outstanding debt, thereby enhancing financial flexibility.
• Welcoming Jason D. Davis as CFO to steer the company through its next phase of growth, backed by over 25 years of financial expertise.

In addition, FibroBiologics showcased its innovations at numerous conferences and authored an op-ed discussing the advantages of fibroblast therapies over traditional stem cell therapies.

Advancements in Clinical Trials

Clinical progress remains at the core of FibroBiologics' mission. Notable achievements from 2025 include:

• Completion and release of the CYWC628 master and working cell banks in collaboration with Charles River, compliant with FDA cGMP standards.
• Receiving HREC approval in Australia for the Phase 1/2 trial of CYWC628 focused on diabetic foot ulcers, set to begin in Q1 2026.
• Filing a new Investigational New Drug (IND) application for the CYPS317 spheroid therapy targeting psoriasis, indicating efficacy comparable to advanced biologics.
• Advancing CYMS101 for multiple sclerosis towards IND submission, leveraging promising remyelination data.

These developments position FibroBiologics for an active clinical trial schedule in 2026, significantly impacting patient's lives across various chronic conditions.

Scientific Research and Intellectual Property

The year also saw groundbreaking strides in scientific research at FibroBiologics. Key highlights include:

• Successful confirmation of remyelination in brain tissue repair models, enhancing FibroBiologics' potential treatment approaches for demyelinating diseases like multiple sclerosis.
• Innovative developments in a bone marrow organoid platform aimed at reducing tumor sizes in cancer models.
• A robust patent portfolio exceeding 270 issued and pending patents, covering diverse applications from wound healing to cancer treatment.

FibroBiologics continues to strengthen its intellectual property, ensuring a competitive edge while paving the way to transformative therapies in cell therapy and tissue regeneration.

Financial Position and Future Outlook

FibroBiologics' financial execution remains disciplined, as demonstrated in its quarterly reports. By the first quarter, investments were heavily directed towards R&D and the lab expansion, followed by securing funding through tranches completing a $25 million financing by the second quarter. Moving into 2026, FibroBiologics aims to:

• Continue executing clinical trials and refining IND submissions.
• Solidify its financial standing.

Despite facing challenges such as regulatory hurdles, the team’s dedication, combined with shareholder support, fuels optimism for overcoming obstacles in the pursuit of medical breakthroughs.

About FibroBiologics

FibroBiologics, based in Houston, focuses on developing innovative treatments using fibroblast cells and fibroblast-derived materials. With a diverse portfolio of over 270 issued patents and patents pending worldwide, FibroBiologics is pioneering advancements in various therapeutic areas, including wound healing, multiple sclerosis, and cancer.

For further information, visit www.FibroBiologics.com or contact the company via email at info@fibrobiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements regarding the expected clinical benefits of FibroBiologics' therapies and research projects. These statements reflect management's current expectations and estimates and involve risks and uncertainties. Actual results may differ materially.